Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06057064 | Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19 | PHASE2 | COMPLETED | 116 | — | — | Sep 29, 2023 | May 17, 2024 | Aug 15, 2025 | 6 | Russia |
The safety profile will be evaluated using vital signs, laboratory data, electrocardiograms (ECGs), and adverse event data
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Single dose of Placebo IM (0.9% sodium chloride) |
| AZD3152 | EXPERIMENTAL | Single dose of 300 mg IM |
| Name | Type | Description |
|---|---|---|
| Biological: AZD3152 | BIOLOGICAL | 300 mg single dose of AZD3152 IM |
| Biological: Placebo | BIOLOGICAL | Single dose of Placebo IM (0.9% sodium chloride) |
Inclusion Criteria: * Participant must be 18 years of age or older at the time of signing the informed consent. * Weight ≥ 45 kg at Visit 1. * Participants must satisfy at least 1 of the following risk factors at enrollment: 1. Obese, ie, BMI ≥ 30 2. Congestive heart failure 3. Chronic obstr...